Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Sponsor
Aristotle University Of Thessaloniki
Study ID
NCT06284850
Status
Unknown

Conditions

  • Cardiovascular Prevention
  • Empagliflozin
  • Hematocrit Change
  • SGLT2-Inhibitors
  • Tissue Oxygenation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin10Mg Tab — DRUG
    TB JARDIANCE 10MG

Study Details

The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and reno- protective effect of SGLT-2 inhibitors.

Key Dates

First listed
Feb 29, 2024
Start date
Nov 30, 2023
Status verified
Feb 2024
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: treatment with empagliflozin 10mg od
    empagliflozin 10mg OD

Primary Outcome Measure

Mean change in red blood cell 2,3-biphosphoglycerate levels (μmol/ml) [ Time Frame: 12 weeks ]

Central Contacts